logo
Share SHARE
FONT-SIZE Plus   Neg

Amgen's PCSK9 Inhibitor Lowers LDL Cholesterol Up To 81%

Amgen Inc. (AMGN) Sunday reported positive results from phase 1b study of AMG 145, an investigational PCSK9 inhibitor, in patients with high cholesterol who were taking statins. The study revealed that multiple doses of the drug significantly reduced LDL, or bad cholesterol, by up to 81 percent compared to placebo in patients on low to moderate doses of statins.

AMG 145 is a fully human monoclonal antibody that inhibits PCSK9, a protein that reduces the liver's ability to remove LDL-C from the blood. High LDL cholesterol is the main contributor to the risk of developing cardiovascular disease.

In the 51-patient study, the subjects who received AMG 145 every two weeks in combination with low to moderate doses of statins had LDL reductions of up to 75 percent versus placebo at sixth week.

Meanwhile, the subjects who received AMG 145 in combination of low to moderate doses of statins every four weeks showed up to a 66 percent reduction in LDL at eighth week.

Patients on high doses of statins who received AMG 145 every two weeks had a reduction in LDL of up to 63 percent versus placebo at sixth week, the company said.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Editors Pick
Takata Corp. will file for bankruptcy protection on Monday as the Japanese airbag maker seeks protection from creditors following billions of dollars in liabilities linked to a massive global recall of defective air bags, Reuters reported Thursday, citing two sources. Troubled mortgage lender Home Capital Group Inc. (HCG.TO) is hoping for a new lease of life with Warren buffet extending a helping hand by way of C$2 billion or $1.5 billion line of credit to its subsidiary Home Trust Co. The credit from the renowned investor will help end the strategic review of the lender and to settle a loan facility from an institutional investor. Cable company Altice USA Inc. increased Wednesday the number of shares it will sell in its initial public offering by 37%, raising around $1.9 billion. In the IPO, the company offered 63.94 million shares at a price of $30 per share, higher than the 46.6 million shares announced last month.
comments powered by Disqus
Follow RTT